Table 2. Treatment response.
| Response | n (%) | |
|---|---|---|
| CR | 36 | (27.27%) |
| PR | 3 | (2.27%) |
| mCR with HI | 8 | (6.06%) |
| mCR without HI | 11 | (8.33%) |
| HI only* | 25 | (18.94%) |
| Patient experienced HI | 72 | |
| SD# | 48 | (36.36%) |
| ORR (CR + PR + mCR + HI) | 83 | (62.88%) |
| 95% CI+ | (54.04% | −71.12%) |
| CR + PR + mCR + HI + SD | 131 | (99.24%) |
| Failure | 1 | (0.76%) |
| Cytogenetic response | 55** | |
| CR | 14 | (25.45%) |
| PR | 5 | (9.09%) |
| NE/ND | 36 | (65.45%) |
CR, complete response; HI, hematologic improvement; HI-E, erythroid response; HI-N, neutrophil response; HI-P, platelet response; IWG, International working group; mCR, marrow complete response; ND, not done; NE, not evaluable; ORR, overall response rate; PR, partial response; SD, stable disease
*
HI only: HI in SD and NE/ND
#
SD excluding other than HI
+
95% confidence interval for proportion of ORR
**
In case of abnormal Karyotype (Good-Other, Intermediate, Poor)